RxDoctor Payments Data

Mechell Smith, NP

Family · Elizabeth City, NCNPI 1538272679

Payments from drug & device makers

$11,921in general payments, 2019–2025

Across 731 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Corcept Therapeutics$1K
  • AstraZeneca$728
  • Lilly USA, LLC$725
  • Bayer$683
  • plus $6K from 34 others

What the payments were for

  • Food & beverage$11,83399%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,921 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$30,143
Medicare patients
205
Services billed
478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$24,045
Synjardy XrEmpagliflozin/Metformin Hcl16$18,678
MounjaroTirzepatide13$18,015
FarxigaDapagliflozin Propanediol20$14,684
TrulicityDulaglutide12$9,081
Albuterol Sulfate HfaAlbuterol Sulfate37$1,772
Estradiol18$1,044
Omeprazole80$1,010
Atorvastatin Calcium122$872
Diclofenac Sodium20$792
Rosuvastatin Calcium89$671
Levothyroxine Sodium72$651
Losartan Potassium51$533
Prednisone58$497
Gabapentin36$455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$725$27,09625 claims
PfizerEliquis$345$24,04522 claims
Boehringer IngelheimSynjardy Xr$262$18,67816 claims
AstraZenecaFarxiga$728$14,68420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Elizabeth City

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →